Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'You're no longer my sister' - rows erupt as war divides Iranian families - 2Fake new headlights rule steer Australian drivers astray
- 3A soft launch, an unfollow and a lot of questions: Breaking down the 'Summer House' romance blowing up group chats
- 4Must-Have Cooking Machine in Your Kitchen
- 5Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- How Much Has the Iran War Cost the Average American Per Day?
- Palestine weekly wrap: Protests sweep West Bank after death penalty law
- Elite Execution Gaming PCs for Gamers
- Sources: IDF does not actually know how many ballistic missiles Iran has left
- What's Your #1 Pizza Beating Mix?
- Israel says Iran's military industry will be destroyed 'within days'
- Find the Lively Food Markets of South America
- A definitive Manual for Choosing Indoor Plants Ideal for Your Space
- Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
